← All trials
NCT01518998
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 2011
- Primary completion
- Oct 1, 2013
- Completion date
- Nov 1, 2013
- First posted
- —
- Last posted
- —
- Enrollment
- 420
- Arms / groups
- 9 / —
- Source
- AACT · pre-existing
Sponsors
- Boryung Pharmaceutical CompanyLead sponsor
- Korea UniversityCollaborator
- Inha UniversityCollaborator
- Inje UniversityCollaborator
- Kangbuk Samsung HospitalCollaborator
- Chonnam National UniversityCollaborator
- Sungkyunkwan UniversityCollaborator
- Daegu Catholic UniversityCollaborator
- Chungnam National UniversityCollaborator
- Seoul National UniversityCollaborator
- Jeju National UniversityCollaborator
- Hanyang UniversityCollaborator
- Yeungnam UniversityCollaborator
- Gachon UniversityCollaborator
- University of UlsanCollaborator
- Boryung Pharmaceutical CompanyStudy director
- Catholic University of KoreaCollaborator
- Dongguk UniversityCollaborator
- Hallym UniversityCollaborator
- Kyungpook UniversityCollaborator
- Soonchunhyang UniversityCollaborator
- Wonju Christian HospitalCollaborator
- Wonkwang UniversityCollaborator
- Pusan National UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.